Stereoselective Genetically-determined Interaction Between Chronic Flecainide and Quinidine in Patients with Arrhythmias

Overview

Journal Br J Clin Pharmacol

Specialty Pharmacology

Date 1992 Mar 1

PMID 1576047

Citations 13

Authors

U M Birgersdotter

W Wong

J Turgeon

D M Roden

Affiliations

Soon will be listed here.

Abstract

1. Recent reports have indicated a role for the P450IID6 polymorphism in the stereoselective disposition of single doses of the antiarrhythmic flecainide. 2. In this study, we evaluated the effects of adding low dose quinidine, a potent inhibitor of P450IID6, to chronic flecainide therapy in patients with arrhythmias. 3. In five extensive metabolizer patients, quinidine significantly reduced the clearance of R-(-)-flecainide, from 395 +/- 121 (s.d.) to 335 +/- 88 ml min-1. This change was attributable to a decrease in metabolic clearance, was accompanied by decreased formation of the two major metabolites of flecainide and was not observed in a poor metabolizer subject. The renal clearance of R-(-)-flecainide rose significantly. 4. Quinidine did not alter the clearance of S-(+)-flecainide. 5. The pharmacologic effects of flecainide therapy (QRS widening, % arrhythmia suppression) were slightly, but not significantly, increased. 6. In extensive metabolizer patients receiving chronic flecainide, increased plasma concentrations will develop if P450IID6 is inhibited.

Citing Articles

Drug-Drug-Gene Interactions in Cardiovascular Medicine.

Asiimwe I, Pirmohamed M Pharmgenomics Pers Med. 2022; 15:879-911.

PMID: 36353710 PMC: 9639705. DOI: 10.2147/PGPM.S338601.

Cytochrome P450-2D6 Genotype Definition May Improve Therapy for Paroxysmal Atrial Fibrillation A Case of Syncope Following "Pill-in-the-Pocket" Quinidine plus Propafenone.

W Daniell M D H J Atr Fibrillation. 2016; 6(5):978.

PMID: 27957038 PMC: 4956126. DOI: 10.4022/jafib.978.

Evaluating the safety and efficacy of dextromethorphan/quinidine in the treatment of pseudobulbar affect.

Schoedel K, Morrow S, Sellers E Neuropsychiatr Dis Treat. 2014; 10:1161-74.

PMID: 25061302 PMC: 4079824. DOI: 10.2147/NDT.S30713.

Impact of genetic polymorphism on drug-drug interactions mediated by cytochromes: a general approach.

Tod M, Nkoud-Mongo C, Gueyffier F AAPS J. 2013; 15(4):1242-52.

PMID: 24027036 PMC: 3787231. DOI: 10.1208/s12248-013-9530-2.

Quantitative prediction of cytochrome P450 (CYP) 2D6-mediated drug interactions.

Tod M, Goutelle S, Clavel-Grabit F, Nicolas G, Charpiat B Clin Pharmacokinet. 2011; 50(8):519-30.

PMID: 21740075 DOI: 10.2165/11592620-000000000-00000.

References

Speirs C, Murray S, Boobis A, Seddon C, Davies D . Quinidine and the identification of drugs whose elimination is impaired in subjects classified as poor metabolizers of debrisoquine. Br J Clin Pharmacol. 1986; 22(6):739-43. PMC: 1401220. DOI: 10.1111/j.1365-2125.1986.tb02969.x. View

Gross A, Mikus G, Fischer C, Hertrampf R, Gundert-Remy U, Eichelbaum M . Stereoselective disposition of flecainide in relation to the sparteine/debrisoquine metaboliser phenotype. Br J Clin Pharmacol. 1989; 28(5):555-66. PMC: 1380016. DOI: 10.1111/j.1365-2125.1989.tb03542.x. View

Kroemer H, Funck-Brentano C, Silberstein D, Wood A, Eichelbaum M, Woosley R . Stereoselective disposition and pharmacologic activity of propafenone enantiomers. Circulation. 1989; 79(5):1068-76. DOI: 10.1161/01.cir.79.5.1068. View

Dayer P, Balant L, Kupfer A, Striberni R, Leemann T . Effect of oxidative polymorphism (debrisoquine/sparteine type) on hepatic first-pass metabolism of bufuralol. Eur J Clin Pharmacol. 1985; 28(3):317-20. DOI: 10.1007/BF00543330. View

Woosley R, Roden D, Dai G, Wang T, Altenbern D, Oates J . Co-inheritance of the polymorphic metabolism of encainide and debrisoquin. Clin Pharmacol Ther. 1986; 39(3):282-7. DOI: 10.1038/clpt.1986.40. View

Munafo A, Biollaz J . High-performance liquid chromatographic assay with fluorometric detection for flecainide and its major metabolites in urine and serum. J Chromatogr. 1989; 490(2):450-7. DOI: 10.1016/s0378-4347(00)82805-4. View

Mikus G, Gross A, Beckmann J, Hertrampf R, Gundert-Remy U, Eichelbaum M . The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther. 1989; 45(5):562-7. DOI: 10.1038/clpt.1989.73. View

Funck-Brentano C, Turgeon J, Woosley R, Roden D . Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. J Pharmacol Exp Ther. 1989; 249(1):134-42. View

Funck-Brentano C, Kroemer H, Pavlou H, Woosley R, Roden D . Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. Br J Clin Pharmacol. 1989; 27(4):435-44. PMC: 1379722. DOI: 10.1111/j.1365-2125.1989.tb05391.x. View

10.

Brosen K, Gram L, Haghfelt T, Bertilsson L . Extensive metabolizers of debrisoquine become poor metabolizers during quinidine treatment. Pharmacol Toxicol. 1987; 60(4):312-4. DOI: 10.1111/j.1600-0773.1987.tb01758.x. View

11.

Walle T, Walle U, Olanoff L, Conradi E . Partial metabolic clearances as determinants of the oral bioavailability of propranolol. Br J Clin Pharmacol. 1986; 22(3):317-23. PMC: 1401138. DOI: 10.1111/j.1365-2125.1986.tb02893.x. View

12.

Inaba T, Tyndale R, Mahon W . Quinidine: potent inhibition of sparteine and debrisoquine oxidation in vivo. Br J Clin Pharmacol. 1986; 22(2):199-200. PMC: 1401106. DOI: 10.1111/j.1365-2125.1986.tb05251.x. View

13.

Brinn R, Brosen K, Gram L, Haghfelt T, Otton S . Sparteine oxidation is practically abolished in quinidine-treated patients. Br J Clin Pharmacol. 1986; 22(2):194-7. PMC: 1401116. DOI: 10.1111/j.1365-2125.1986.tb05250.x. View

14.

Morganroth J, Anderson J, Gentzkow G . Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol. 1986; 8(3):607-15. DOI: 10.1016/s0735-1097(86)80190-5. View

15.

Guehler J, Gornick C, Tobler H, Almquist A, Schmid J, Benson Jr D . Electrophysiologic effects of flecainide acetate and its major metabolites in the canine heart. Am J Cardiol. 1985; 55(6):807-12. DOI: 10.1016/0002-9149(85)90161-4. View

16.

Zhou H, Anthony L, Roden D, Wood A . Quinidine reduces clearance of (+)-propranolol more than (-)-propranolol through marked reduction in 4-hydroxylation. Clin Pharmacol Ther. 1990; 47(6):686-93. DOI: 10.1038/clpt.1990.94. View

17.

Turgeon J, Kroemer H, Prakash C, Blair I, Roden D . Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with fluorescence detection. J Pharm Sci. 1990; 79(2):91-5. DOI: 10.1002/jps.2600790202. View

18.

Lee J, Kroemer H, Silberstein D, Funck-Brentano C, Lineberry M, Wood A . The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. N Engl J Med. 1990; 322(25):1764-8. DOI: 10.1056/NEJM199006213222502. View

19.

Carey Jr E, Duff H, Roden D, Primm R, Wilkinson G, Wang T . Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. J Clin Invest. 1984; 73(2):539-47. PMC: 425046. DOI: 10.1172/JCI111241. View

20.

Elharrar V, Zipes D . Effects of encainide and metabolites (MJ14030 and MJ9444) on canine cardiac Purkinje and ventricular fibers. J Pharmacol Exp Ther. 1982; 220(2):440-7. View